DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that it has entered into a Sponsored Research Agreement with the Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) for research on a new, more potent and longer-acting form of the anemia drug Erythropoietin (EPO).
